clonal evolution of aml on novel fms-like tyrosine kinase-3 (flt3) inhibitor therapy with evolving actionable targets
Clicks: 123
ID: 144979
2016
For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clinical trial (ASP2215) to show that employing therapeutic interventions with these novel targeted therapies can lead to consequences secondary to selective pressure and clonal evolution of cancer. We describe novel findings alongside data on treatment directed towards actionable aberrations acquired during the process. (Clinical Trial: NCT02014558; registered at: 〈https://clinicaltrials.gov/ct2/show/NCT02014558〉)
| Reference Key |
kasi2016leukemiaclonal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Pashtoon M. Kasi;Mark R. Litzow;Mrinal M. Patnaik;Shahrukh K. Hashmi;Naseema Gangat |
| Journal | urology annals |
| Year | 2016 |
| DOI | 10.1016/j.lrr.2016.01.002 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.